Chemokines constitute a large family of secreted proteins that function as chemoattractants and activators of leukocytes. Astrocytes, the major glial cell type in the central nervous system (CNS), are a source of chemokine production within diseased brain. As such, we have examined the production of chemokines by human astroglioma cell lines and primary human astrocytes treated with a variety of stimuli, including LPS, TNF-a, IFN-g and IL-1b. In addition, IL-6 in conjunction with the soluble IL-6 receptor (sIL-6R), and hybrid IL-6 (H-IL-6), a highly active fusion protein of sIL-6R and IL-6, were tested for their ability to induce chemokine expression. The ®ndings presented herein demonstrate that both human astroglioma cell lines and primary human astrocytes express the CXC chemokines IP-10 and IL-8 and the CC chemokines MCP-1 and RANTES in response to TNF-a and IL-1b. IFN-g induced the expression of IP-10, but not of IL-8, MCP-1 or RANTES. Surprisingly, IL-6/sIL-6R and H-IL-6 had little or no effect on chemokine expression in these cells. The effect of TGF-b on chemokine expression in human astroglioma cell lines and astrocytes was also examined. TGF-b alone had little or no effect on RANTES, MCP-1 and IL-8 expression; however, TGF-b synergized with TNF-a to enhance MCP-1 expression in both astroglioma cells and primary astrocytes. An inhibitory effect of TGF-b on TNF-a and IL-1b induced RANTES and IL-8 expression was observed in human astroglioma cells. In contrast, TGF-b enhanced TNF-a and IL-1b induction of IL-8 production by human astrocytes. These ®ndings document a complex pattern of chemokine regulation by the pleiotropic cytokine TGF-b with both enhancing and inhibitory effects.
Introduction
The chemokines are small molecular weight (5 ± 12 kDa) secreted proteins that mediate the recruitment and activation of leukocytes and other cells to sites of in¯ammation during an immune response. Chemokines are the products of four related gene families, members of which exhibit sequence homology and structural similarities (for review see Baggiolini, 1998; Luster, 1998; Rollins, 1997) . The chemokines have been subdivided into the four families based on the arrangement of the ®rst two of four conserved cysteine residues. In the a chemokine family, one amino acid separates the ®rst two cysteine residues (cysteine-X-cysteine, or CXC). In general, CXC chemokines are chemotactic for neutrophils, T-cells and natural killer (NK) cells.
Members of the CXC family include interleukin-8 (IL-8), IFN-g-inducible protein, 10 kDa (IP-10), GROa, b and g, monokine induced by IFN-g (MIG) , and stromal cell-derived factor (SDF)-1a and b. The b chemokine family is characterized by the ®rst two cysteine residues being adjacent to each other (cysteine-cysteine, or CC). Members of the CC family include macrophage in¯ammatory protein (MIP)-1a, MIP-1b, monocyte chemoattractant protein-1 (MCP-1), MCP-2, MCP-3, RANTES, eotaxin and thymus and activation-regulated chemokine (TARC). The predominant biological effects of CC chemokines are serving as chemoattractants for monocytes/macrophages, activated T-cells, B-cells, eosinophils, basophils and dendritic cells (for review see Rollins, 1997) . Two new chemokine families have recently been described. Lymphotactin, a chemoattractant for T-cells, lacks two of the four cysteine residues, and is characterized as a`C' chemokine (Kelner et al, 1994) . A recently cloned chemokine (fractalkine or neurotactin) is a membrane bound glycoprotein in which the ®rst two cysteine residues are separated by three amino acids (CX 3 C) (Bazan et al, 1997; Pan et al, 1997) . This chemokine functions as a chemoattractant for T-cells and monocytes, is highly expressed in brain and upregulated by in¯ammatory events (Bazan et al, 1997; Pan et al, 1997) .
Chemokines are expressed locally in response to in¯ammatory stimuli, and act to recruit leukocytes via their chemoattractant properties and ability to induce integrin activation. More recently, other important physiological functions have been ascribed to chemokines, including angiogenic activity, angiostatic properties, and modulation of T-cell cytokine production (for review see Rollins, 1997) . Aberrant expression of various chemokines has been implicated in contributing to the pathogenesis of neurologic diseases such as multiple sclerosis (MS), AIDS dementia complex (ADC), Alzheimer's disease, bacterial meningitis, astrocytic tumors, cerebral ischemia and trauma (Conant et al, 1998; Desbaillets et al, 1994; McManus et al, 1998a; Ransohoff and Tani, 1998; Sacca et al, 1997; Schmidtmayerova et al, 1996; Spanaus et al, 1997) . Chemokines are expressed in the central nervous system (CNS) of animals with experimental allergic encephalomyelitis (EAE), a model of MS. In SJL/J mice undergoing EAE, astrocytes were the only cells in the CNS which expressed mRNA transcripts for MCP-1 and IP-10. Furthermore, chemokine expression correlated with the appearance of clinical and histologic EAE (Ransohoff et al, 1993) . In the Lewis rat, levels of MCP-1 mRNA were elevated immediately before the onset of clinical signs, peaked with the height of disease, and declined with resolution of disease (Hulkower et al, 1993) ; the elevation of MCP-1 at the height of clinical disease also correlated with extensive perivascular accumulation of monocytes. The cellular sources of MCP-1 were identi®ed as macrophages, lymphocytes and endothelial cells . Also in the Lewis rat, IL-8 was expressed at the peak of disease, and declined upon recovery (Khoury et al, 1992) . Analysis from animals with both actively induced and adoptively transferred EAE demonstrated that mRNAs encoding RANTES, MIP-1a, MIP-1b, IP-10 and MCP-1 were induced prior to clinical signs, and achieved highest levels at disease onset (Godiska et al, 1995; Miyagishi et al, 1997) . Many of the same chemokines have been detected in other animal models of CNS disease including mechanical injury/trauma, ischemia, virus-induced demyelination, and SIVinduced encephalitis Glabinski et al, 1996; Gourmala et al, 1997; Grzybicki et al, 1998; Lane et al, 1998; Sasseville et al, 1996) . These ®ndings collectively indicate that expression of both CC and CXC chemokines which speci®cally target cells of the immune system such as T-cells, Bcells and macrophages, are an important component of numerous CNS diseases.
Some of the in vivo studies mentioned above indicate that astrocytes are a source of chemokine production within the diseased brain (Glabinski et al, 1997; McManus et al, 1998a; Ransohoff et al, 1993; Schmidtmayerova et al, 1996) . Astrocytes are the major glial cell type in the CNS, and upon stimulation can secrete a wide variety of cytokines, as well as express adhesion molecules such as ICAM-1 and VCAM-1 (for review see Merrill and Benveniste, 1996) . A growing literature also suggests that astrocytes can be activated to produce chemokines such as RANTES, IL-8, IP-10, MCP-1, MIP-1a, and MIP-1b (Aloisi et al, 1992; Barna et al, 1994; Barnes et al, 1996; Hayashi et al, 1995; Hurwitz et al, 1995; Kasahara et al, 1991; Sun et al, 1997; Vanguri and Farber, 1994) . In this study, we have examined chemokine production by human astroglioma cell lines and primary human astrocytes in response to a variety of stimuli including LPS, TNF-a, IL-1b and IL-6. IL-6 was included as it is a strong inducer of chemokine production by endothelial cells and monocytes (Biswas et al, 1998; Romano et al, 1997) . In addition, we tested the in¯uence of TGF-b on chemokine expression, since TGF-b has been shown to have potent inhibitory effects on astrocytes such as suppressing class II MHC, VCAM-1, ICAM-1 and TNF-a gene expression (Benveniste et al, 1994; Lee et al, 1997; Shrikant et al, 1996; Winkler and Benveniste, 1998) . As well, TGF-b has complex biologic actions on chemokine production, depending on the cell type under investigation (Aloisi et al, 1992; Chen and Manning, 1996; Ehrlich et al, 1998; Hurwitz et al, 1995; Smith et al, 1996) .
Results
Cytokine modulation of chemokine mRNA expression in human astroglioma cells and primary human astrocytes Two human astroglioma cell lines, U251-MG and U373-MG, were tested for their ability to express chemokine mRNA in response to a variety of stimuli. LPS, a strong inducer of chemokine gene expression in various cell types (Hayashi et al, 1995; Meda et al, 1996; Peterson et al, 1997) was utilized, as were the proin¯ammatory cytokines TNF-a, IL-1b and IFN-g. As well, IL-6 in conjunction with the soluble IL-6 receptor (sIL-6R), and hybrid IL-6 (H-IL-6), a highly active fusion protein of sIL-6R and IL-6 (Fischer et al, 1997) , were tested for their ability to induce chemokine expression. The concentrations of LPS, TNF-a, IL-1b, IFN-g, IL-6/sIL-6R and H-IL-6 used in this study have been shown by our laboratory to induce functional changes in glioma cells, such as expression of ICAM-1, VCAM-1 and class II MHC, as well as tyrosine phosphorylation of STAT-1a and STAT-3 (Ballestas and Benveniste, 1997; Lee et al, 1997; Oh et al, 1998; Winkler and Benveniste, 1998) . Cells were stimulated for 10 h, RNA extracted, then analyzed by ribonuclease protein assay (RPA) for chemokine mRNA expression. As shown in Figure 1 , U251-MG and U373-MG constitutively express mRNA for the CC chemokine MCP-1 (lanes 2 and 9), and LPS, TNF-a, and IL-1b enhance MCP-1 mRNA expression (lanes 3, 4, 6, 10, 11 and 13) . Of the two cell lines, U373-MG cells were more responsive to TNF-a and IL-1b regarding MCP-1 mRNA enhancement. IFN-g, IL-6/sIL-6R or H-IL-6 treatment had no signi®cant effect on constitutive MCP-1 mRNA levels in either cell line. RANTES, another CC chemokine, was induced by Figure 1 Ribonuclease protection assay for chemokine mRNA expression by human astroglioma cell lines. U251-MG cells (lanes 2 ± 8) and U373-MG cells (lanes 9 ± 15) were incubated with medium alone (lanes 2 and 9), LPS (1 mg/ml; lanes 3 and 10), TNF-a (10 ng/ ml; lanes 4 and 11), IFN-g (100 U/ml; lanes 5 and 12), IL-1b (4 ng/ml; lanes 6 and 13), IL-6 (10 ng/ml) plus sIL-6R (100 ng/ml; lanes 7 and 14), or H-IL-6 (20 ng/ml; lanes 8 and 15) for 10 h, then RNA was isolated and analyzed for chemokine mRNA expression by RPA. Probe alone is shown in lane 1. Representative of four experiments.
IL-1b in U373-MG cells (lane 13). None of the other CC chemokines examined, MIP-1a, MIP-1b or I-309, were inducible in the human astroglioma cells under the conditions tested in this study. Two CXC chemokines, IP-10 and IL-8, were inducible in both cell lines in response to TNF-a and IL-1b (lanes 4, 6, 11 and 13). LPS was a modest inducer of IL-8 mRNA expression in the U251-MG cell line (*threefold enhancement above constitutive levels; lane 3), but was not as potent as either TNF-a or IL1b for IL-8 induction. As well, IFN-g induced IP-10 expression in U373-MG cells (lane 12). Lymphotactin, the sole member of the C chemokine family, was not inducible by any of the stimuli tested in this study. Quantitation of the data shown in Figure 1 as well as three other experiments is presented in Figures 2 and 3 . Thus, human astroglioma cells express mRNA for two CC chemokines, MCP-1 and RANTES, and two CXC chemokines, IP-10 and IL-8, upon cytokine stimulation.
We next tested primary cultures of human adult astrocytes for their ability to express chemokine mRNA. MCP-1 mRNA was constitutively expressed in primary astrocytes, and LPS, TNF-a, IFN-g and IL-1b enhanced expression of MCP-1 mRNA ( Figure 4 ; lanes 2 ± 6). Interestingly, IL-6/sIL-6R and H-IL-6 treatment modestly enhanced MCP-1 expression (lanes 7 and 8). It should be noted that lane 7 is underloaded; quantitation of MCP-1 mRNA in relation to GAPDH mRNA levels revealed a 2.5-fold enhancement in MCP-1 mRNA upon IL-6/sIL-6R stimulation (see Figure 5A ). RANTES mRNA expression was strongly inducible by TNF-a and IL-1b (lanes 4 and 6). Similar to the human astroglioma cells, the other CC chemokines, MIP-1a, MIP-1b and I-309, were not expressed in human adult astrocytes. IP-10 and IL-8, two CXC chemokines, were inducible in response to LPS, TNF-a and IL1b (lanes 3, 4 and 6). In addition, IFN-g was a strong stimulator of IP-10 expression in human astrocytes (lane 5). Quantitation of the data shown in Figure 4 and one additional experiment is presented in Figure 5 . Figure 1 and three others (mean value) is depicted. Constitutive expression of chemokine mRNA was set at 1.0, and cytokine treatments were compared to control levels to arrive at the fold induction value.
Kinetic analysis of MCP-1, RANTES, IP-10 and IL-8 mRNA expression Using TNF-a as the stimulus, we examined the kinetics of chemokine mRNA expression in U251-MG astroglioma cells and primary human astrocytes. In U251-MG cells, IP-10 mRNA was ®rst detectable 4 h after stimulation, peaked at 8 h, then rapidly declined with time ( Figure 6 ). In contrast, MCP-1 and IL-8 mRNA were rapidly inducible by TNF-a stimulation (within 1 h), and levels remained elevated up to at least 24 h ( Figure 6 ). RANTES mRNA was not detected since TNF-a is a poor inducer of RANTES in U251-MG cells (see Figure 2 ). In primary adult astrocytes, RANTES and IP-10 mRNA expression was not detectable until 4 h after TNF-a stimulation, and levels peaked between 8 ± 12 h ( Figure 6 ). MCP-1 and IL-8 mRNA levels had already reached optimal levels after a 1 h stimulation period with TNF-a, and levels remained elevated until 12 h. Thus, MCP-1 and IL-8 mRNA expression was rapidly inducible (within 1 h) and remained sustained over a long time period (12 ± 24 h), while IP-10 and RANTES (for human astrocytes) mRNA appeared with delayed kinetics (4 h).
RANTES, MCP-1 and IL-8 protein expression in astrocytes
We next examined chemokine protein expression by U373-MG, U251-MG, and human astrocytes in response to the stimuli that induced mRNA expression. Comparable results were obtained using U373-MG and U251-MG cells, thus, only data from the U373-MG cell line is presented. Analysis of RANTES protein expression demonstrated that TNF-a and IL-1b could induce picogram (pg) quantities of RANTES by both U373-MG cells and human astrocytes (Table 1) . As well, TNF-a and IL1b were strong inducers of MCP-1 and IL-8, with IL1b being the most potent stimuli for IL-8 production (Table 1 ). These data indicate that chemokine mRNA and protein expression are coordinately regulated in astrocytes.
The in¯uence of TGF-b1 on RANTES, MCP-1 and IL-8 protein expression was next analyzed. In U373- Figure 1 and three others (mean value) is depicted. Constitutive expression of chemokine mRNA was set at 1.0 and cytokine treatments were compared to control levels to arrive at the fold induction value.
MG cells, TGF-b1 alone had no in¯uence on RANTES expression, but caused a signi®cant inhibition of TNF-a and IL-1b induced RANTES expression (*94% and *80% inhibition, respectively; Table 1 ). This is in contrast to RANTES production by human astrocytes, where TGF-b1 modestly inhibited TNF-a induced RANTES expression (*25% inhibition), but had no in¯uence on IL-1b induced RANTES (Table 1) . A different pattern was observed for MCP-1 expression. TGF-b1 alone induced MCP-1 protein production in U373-MG cells, and synergized with TNF-a for signi®cant enhancement of MCP-1 expression (Table 1) . Interestingly, TGF-b did not synergize with IL-1b for enhanced MCP-1 production. In human astrocytes, TGF-b1 augmented TNF-a induced MCP-1 expression, while having no in¯uence on IL-1b induced MCP-1 expression (Table 1) . Lastly, for IL-8 expression, TGF-b1 alone had no effect on IL-8 production in U373-MG cells, but inhibited TNF-a and IL-1b induced IL-8 expression by *64% and *84%, respectively (Table 1 ). In contrast, IL-8 production by human astrocytes in response to TNF-a and IL-1b was enhanced in the presence of TGF-b1. These results indicate that TGF-b1 has a complex effect on RANTES, MCP-1 and IL-8 production, which appears to be both chemokine and stimulus-speci®c.
Discussion
Upregulation of chemokine expression in the CNS may be a contributing factor to diseases such as MS and ADC (Conant et al, 1998; McManus et al, 1998a; Schmidtmayerova et al, 1996) . As such, it is cirtical to delineate the cell sources within the CNS capable of producing chemokines, and the stimuli that regulate expression. In this study, we demonstrate that human astroglioma cells/astrocytes can be induced to express two CXC chemokines, IP-10 and IL-8, as well as two CC chemokines, MCP-1 and RANTES. TNF-a and IL-1b, two proin¯ammatory cytokines that have been implicated in contributing to in¯ammation within the CNS, are strong inducers of all four chemokines. As well, IFN-g, another proin¯ammatory cytokine, had a potent inducing effect for IP-10 expression, but not IL-8, MCP-1 or RANTES. In addition, we document a complex pattern of chemokine regulation by the immunosuppressive cytokine, TGF-b, with both enhancing and inhibitory effects.
IL-8, a potent chemoattractant and activator of neutrophils, is produced by a wide variety of cell types including T-cells, monocytes, neutrophils, endothelial cells, ®broblasts, microglia and astrocytes (for review see Rollins, 1997) . Astrocytes have previously been shown to produce IL-8 in response to TNF-a and IL-1b, with IL-1b being the more potent inducer (Aloisi et al, 1992; Ehrlich et al, 1998; Kasahara et al, 1991) . Our ®ndings con®rm these previous ®ndings, and demonstrate coordinate regulation of IL-8 mRNA and protein expression. We also tested the in¯uence of IL-6 on IL-8 production by astrocytes. Endothelial cells have been shown to produce IL-8 in response to IL-6 plus the soluble IL-6R (Romano et al, 1997) . We have Figure 4 Ribonuclease protection assay for chemokine mRNA expression by human adult astrocytes. Astrocytes were incubated with medium (lane 2), LPS (1 mg/ml; lane 3), TNF-a (10 ng/ ml; lane 4), IFN-g (100 U/ml; lane 5), IL-1b (4 ng/ml; lane 6), IL-6 (10 ng/ml) plus sIL-6R (100 ng/ml; lane 7), or H-IL-6 (20 ng/ml; lane 8) for 10 h, then RNA was isolated and analyzed for chemokine mRNA expression by RPA. Probe alone is shown in lane 1. Representative of two experiments. recently demonstrated that human astroglioma cells/astrocytes can be stimulated by IL-6 plus the soluble IL-6R to induce tyrosine phosphorylation of STAT-3, as well as inhibit VCAM-1 expression (Oh et al, 1998) . These results indicate that upon inclusion of the soluble IL-6R, astrocytes are rendered responsive to IL-6 (Oh et al, 1998) . Interestingly, IL-6 plus sIL-6R or H-IL-6 did not induce IL-8 production by astrocytes/astroglioma cells, suggesting that IL-8 is produced in a cell-type and stimulus-speci®c manner. Although the astroglioma cell lines and primary human astrocytes were induced to express IL-8 in a comparable fashion, they responded in a distinct manner to the inclusion of TGF-b. TGF-b inhibited both TNF-a or IL-1b induced IL-8 expression in U373-MG and U251-MG cells, with a stronger inhibitory effect on IL-1b induced IL-8 production. This result is similar to that observed in endothelial cells and microglia, where TGF-b has been shown to inhibit TNF-a, IL1b or LPS-induced IL-8 production (Chen and Manning, 1996; Ehrlich et al, 1998; Smith et al, 1996) . IL-8, a chemokine with angiogenic and chemotactic properties, is upregulated in astroglioma cell lines in response to ischemic/hypoxic conditions (Desbaillets et al, 1997) . It has been speculated that this enhanced IL-8 production may contribute to tumor neovascularization. TGF-b may have a bene®cial role in downregulating IL-8 production by glioma cells, thereby restricting tumor-induced neovascularization and subsequent progression of the tumor. However, in human adult astrocytes, TGF-b enhanced TNF-a or IL-1b induced IL-8 expression, which is in contrast to the inhibitory effect on astroglioma cells, endothelial cells and microglia. The molecular basis of TGF-b modulation of IL-8 gene expression is not known, but likely involves both transcriptional/post-transcriptional effects (Ehrlich et al, 1998; Smith et al, 1996) . Future experiments will focus on understanding the differential effect of TGF-b on IL-8 gene expression in astroglioma cells versus primary astrocytes. It will also be important to determine the functional signi®cance of IL-8 in neuroimmunologic disease compared to progression of brain tumors. Figure 4 and one other (mean value) is depicted. Constitutive expression of chemokine mRNA was set at 1.0, and cytokine treatments were compared to control levels to arrive at the fold induction value.
IP-10, another CXC chemokine, is chemotactic for monocytes and CD4 + memory cells, but not for neutrophils (for review see Farber, 1997) . A striking increase in IP-10 expression occurs during relapse of chronic EAE, and astrocytes have been identi®ed as the in vivo source of IP-10 (Glabinski et al, 1997) . In vitro, IP-10 is inducible in astrocytes in response to TNF-a, IL-1b and IFN-g (Vanguri and Farber, 1994 ) (this study). Although IP-10 is generally considered as a strongly IFN-g inducible gene product (for review see Farber, 1997) , in astroglioma cells, it appears that TNF-a and IL-1b are more potent inducers than IFN-g. The TNF-a/IL-1b response in astroglioma cells may be mediated by Figure 6 Kinetic analysis of chemokine mRNA expression. Human adult astrocytes (lanes 1 ± 6) and U251-MG cells (lanes 7 ± 13) were incubated with TNF-a (10 ng/ml) for various periods of time (0 ± 24 h). RNA was isolated and analyzed for chemokine mRNA expression by RPA. Representative of two experiments.
the NF-kB sites located in the IP-10 promoter (Ohmori and Hamilton, 1993) . As well, IP-10 can be induced in astrocytes by Newcastle Disease Virus and mouse hepatitis virus (Fisher et al, 1995; Lane et al, 1998; Vanguri and Farber, 1994) . Thus, IP-10, a chemoattractant for lymphocytes and monocytes, can be induced by a variety of stimuli in cells of glial origin. The effect of TGF-b1 on IP-10 protein expression was not examined in this study.
MCP-1 is a CC chemokine that attracts monocytes, memory T-cells and NK cells. MCP-1 de®-cient mice are impaired in monocyte recruitment in several in vivo in¯ammatory models (Lu et al, 1998) , documenting MCP-1's importance in mediating in¯ammatory events. Within the diseased CNS, hypertrophic and reactive astrocytes are a major source of MCP-1 mRNA and protein (McManus et al, 1998a) . In vitro, MCP-1 mRNA and protein is constitutively produced by astrocytes, and expression is enhanced upon treatment with LPS, TNF-a and IL-1b (Barna et al, 1994; Hayashi et al, 1995; Hurwitz et al, 1995) , this study. Infection of astrocytes with mouse hepatitis virus also enhances MCP-1 expression (Lane et al, 1998) . Treatment of astroglioma cells with IL-6 plus the sIL-6R or H-IL-6 does not enhance MCP-1 expression, in contrast to endothelial cells, which are highly inducible for MCP-1 expression in response to IL-6/sIL-6R (Romano et al, 1997) . In primary human astrocytes, IL-6/sIL-6R and H-IL-6 were modest enhancers of MCP-1 mRNA expression, suggesting differences in MCP-1 production by astroglioma cells and primary astrocytes. For MCP-1 expression, we observed that TGF-b1 alone had a minimal effect, but synergized with TNF-a for enhanced expression in both U373-MG and human astrocytes. This is in keeping with previous observations from Hurwitz et al (1995) , who noted a synergistic effect of TNF-a and TGF-b1 on MCP-1 expression in fetal astrocytes. However, a consistent observation from our study was that TGF-b1 did not potentiate IL-1b induced MCP-1 expression in either U373-MG cells or human astrocytes. This implies that TNF-a and IL-1b mediated enhancement of MCP-1 may occur through different mechanisms; only one of which (the TNF-a response) TGF-b1 is able to enhance. Thus, TGF-b, a cytokine which has been implicated in preventing entry of leukocytes into the CNS, possibly by inhibiting expression of adhesion molecules (Fabry et al, 1995; Shrikant et al, 1996) , also has the ability to enhance expression of MCP-1, which would facilitate leukocyte traf®cking into the CNS. It is likely that prevention of leukocyte attachment to endothelial cells of the blood-brain barrier by downregulation of adhesion molecules may be the more prominent aspect of TGF-b activity.
RANTES, a CC chemokine with potent chemotactic activity for monocytes and T-cells, can be weakly induced in astrocytes by TNF-a or IL-1b, with IFN-g having no effect (Barnes et al, 1996) . Our results from this study indicate that in U373-MG cells and human astrocytes, TNF-a and IL-1b are weak inducers of RANTES protein expression, although detection of RANTES mRNA by RPA did not consistently reveal mRNA expression. Certainly of all the chemokines examined, RANTES expression was the lowest upon stimulation. For RANTES, TGF-b1 alone did not induce expression in U373-MG cells or human astrocytes, and strongly inhibited TNF-a or IL-1b induced RANTES in U373-MG cells. The in¯uence of TGF-b1 on RANTES expression has not been examined before, although in endothelial cells and airway smooth muscle cells, RANTES expression is partially inhibited by the Th2 cytokines IL-4, IL-10 and IL-13 Marfaing-Koka et al, 1995) . Thus, it appears that four cytokines with immuno- suppressive properties, TGF-b, IL-4, IL-10 and IL-13, can inhibit RANTES expression in a variety of cell types.
Our results indicate that human astroglioma cells/human astrocytes do not express mRNA for two other CC chemokines, MIP-1a and MIP-1b. This is in contrast to two other studies that demonstrated astrocyte production of MIP-1a and MIP-1b in response to TNF-a, IL-1b, or LPS (Murphy et al, 1995; Peterson et al, 1997) . Possible differences with our study are the source of astrocytes tested; Peterson et al (1997) used human fetal astrocytes, while Murphy et al (1995) tested mouse cortical astrocytes. It appears from other investigators that microglia are a more signi®cant source of MIP-1a and MIP-1b than astrocytes (McManus et al, 1998b) . In vivo studies have suggested that both T-cells and macrophages express MIP-1a and MIP-1b in the CNS of animals with EAE (Glabinski et al, 1997; Miyagishi et al, 1997) .
In summary, the results of this study demonstrate that upon activation with selective stimuli, astrocytes are capable of producing a number of CC and CXC chemokines (MCP-1, RANTES, IP-10, IL-8). These chemokines collectively could participate in the recruitment of T-cells, B-cells and macrophages from the periphery into CNS parenchyma. Given the importance of astrocytes to the structural integrity of the blood-brain barrier, chemokine production at that site would be optimal for promoting extravasation of leukocytes into the CNS. MCP-1 has been shown to be chemotactic for both astrocytes and microglia (Hayashi et al, 1995; Heesen et al, 1996; Peterson et al, 1997) , thus, in disease states, astrocyte and microglial migration to sites of in¯ammation or injury could be mediated by endogenous sources of MCP-1. More recent data reveal that chemokine-chemokine receptor interactions, speci®cally SDF-1 and its receptor CXCR4, are critical for the embryological development of neuronal networks in the CNS (Zou et al, 1998) . It is clear, then, that chemokines have broader functional properties than initially anticipated, and with respect to the CNS, are important for both in¯am-matory and developmental events within this organ.
Materials and methods
Cells U373-MG human astroglioma cells were maintained in MEM with 1 mM Earles BSS media with 2 mM L-glutamine, 100 u/ml penicillin, 100 mg/ml streptomycin, and 10% heat inactivated fetal bovine serum. U251-MG human astroglioma cells were maintained in HAM's/F-12 DMEM medium with 2 mM L-glutamine, 100 u/ml penicillin, 100 mg/ml streptomycin, and 10% heat-inactivated fetal bovine serum. For passage, monolayers were rinsed with PBS and then dislodged by trypsinization (0.25% trypsin, 0.02% EDTA). Biopsy material from patients undergoing surgery to treat intractable epilepsy were used to prepare human adult astrocyte cultures as previously described (Barnum et al, 1992) . Astrocytes were obtained after 30 days in culture, and were 87 ± 93% GFAP positive (Barnum et al, 1992; Oh et al, 1998) . We have previously determined that numerous biological responses of the human astrocytes are comparable to those observed in primary rat and mouse astrocyte cultures (Barnum et al, 1992; Winkler and Benveniste, 1998) .
Reagents
Human recombinant TNF-a and IL-1b were purchased from Genzyme (Cambridge, MA), and human recombinant sIL-6R, IL-6 and TGF-b1 were purchased from R&D Systems (Minneapolis, MN) . Hybrid-IL-6 (H-IL-6) was prepared as previously described (Fischer et al, 1997) . Human recombinant IFN-g was the generous gift of Biogen (Cambridge, MA). Lipopolysaccharide (LPS) was from Sigma Chemical Company (St. Louis, MO).
RNA isolation, riboprobes and RNase protection assay (RPA) Total cellular RNA was isolated from cell monolayers that were incubated for various time periods with the different cytokines as previously described (Shrikant et al, 1995) . Brie¯y, cells were isolated once with PBS and lysed directly in the culture dish. RNA was extracted with guanidinium isothiocyanate and phenol and precipitated with ethanol.
A linearized human chemokine multi-probe set (hCK-5, Catalog #45035P, Pharmingen, San Diego, CA) was in vitro transcribed with T7 RNA polymerase, resulting in ten anti-sense RNA probes. The probes generated from this kit are as follows: lymphotactin (433 nt, 404 nt protected), RANTES (390 nt, 361 nt protected), IP-10 (349 nt, 320 nt protected), MIP-1b (314 nt, 285 nt protected), MIP1a (256 nt, 227 nt protected), MCP-1 (231 nt, 202 nt protected), IL-8 (204 nt, 181 nt protected), I-309 (191 nt, 162 nt protected), L32 (141 nt, 113 nt protected), and GAPDH (124 nt, 96 nt protected).
RNase protection assay (RPA) was carried out with a RPA kit according to the manufacturer's instructions (Pharmingen, San Diego, CA). Brie¯y, 30 mg of total cellular RNA was hybridized with hCK-5 riboprobes (3.1610 5 c.p.m.) in 20 ml of 40 mM PIPES pH 6.4, 80% deionized formamide, 400 mM NaOAc and 1 mM EDTA in a heat block prewarmed to 908C. The temperature was immediately turned down to 568C, and hybridization proceeded for 12 ± 16 h. The hybridized mixture was then treated with RNase A/T1 (1 : 200 dilution in 200 ml of RNase digestion buffer) at 308C for 1 h, RNA was precipitated, and analyzed by 5% denaturing (8 M urea) polyacrylamide gel electrophoresis. The gels were exposed to X-ray ®lm and quantitation of protected RNA fragments was performed by scanning with the PhosphorImager (Molecular Dynamics, Sunnyvale, CA). Values for each chemokine mRNA were normalized to GAPDH mRNA levels for each experimental condition.
Measurement of chemokine production U373-MG cells or human adult astrocytes were incubated with medium alone, TNF-a, TGF-b1, IL1b, TNF-a plus TGF-b1, or IL-1b plus TGF-b1 for 24 h in 6 well plates, then supernatants were collected, centrifuged, and stored at 7708C until use. Equivalent numbers of cells (2610 5 )/well were in each sample. RANTES, MCP-1 and IL-8 in culture supernatants were quantitated using a dual-antibody solid phase ELISA (Biosource International, Camarillo, CA), according to the manufacturer's instructions. Brie¯y, supernantants were diluted 1 : 2 for RANTES detection, and 1 : 100 ± 1 : 500 for MCP-1 and IL-8 in the sample dilution buffer provided with the ELISA kit. The diluted supernatants and recombinant chemokines (as standards) were applied to the wells. Unbound protein was removed by washing, and biotin-conjugate and then horseradish peroxidase-conjugated streptavidin were added in a step-wise manner. After the color reaction with substrate, the optical density was recorded at 450-nm wavelength with an automated ELISA reader. RANTES, MCP-1 and IL-8 concentrations were determined in relation to the standard curve generated with recombinant chemokines provided by the manufacturer. The minimal detection limit for the RANTES ELISA is 3 pg/ml, for MCP-1 20 pg/ml, and for IL-8 10 pg/ml.
Statistical analysis
Levels of signi®cance for comparisons between samples were determined using student's t-test distribution.
